Press releases
- Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
- Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
- Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte Announces First Quarter 2024 Financial Results
- 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
More ▼
Key statistics
On Friday, Veracyte Inc (12V:DEU) closed at 22.00, -16.67% below its 52-week high of 26.40, set on Jan 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.80 |
---|---|
High | 22.00 |
Low | 21.80 |
Bid | 21.60 |
Offer | 22.00 |
Previous close | 22.00 |
Average volume | 79.60 |
---|---|
Shares outstanding | 76.45m |
Free float | 75.82m |
P/E (TTM) | -- |
Market cap | 1.81bn USD |
EPS (TTM) | -0.9346 USD |
Data delayed at least 15 minutes, as of Jul 26 2024.
More ▼